{"disease": "liver cancer", "drug": "ARRY-142886 (Selumetinib)", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["Selumetinib in Treating Patients With Liver Cancer [https://clinicaltrials.gov/study/NCT00553332]", "AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT01029418]", "A Phase I Study of MK-2206 and AZD6244 Hydrogen Sulfate in Patients With Biliary Cancer [https://clinicaltrials.gov/study/NCT01859182]", "A Phase I Study of AZD6244 in Patients With Advanced Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT00604721]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. [https://pubmed.ncbi.nlm.nih.gov/27956228/]", "Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/17237274/]"]}}
{"disease": "liver cancer", "drug": "ARRY-162 (Binimetinib)", "Q1": {"selection": "No", "clinicaltrial_references": ["NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas [https://clinicaltrials.gov/study/NCT02465060]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "AZD6244 (Selumetinib)", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["Selumetinib in Treating Patients With Liver Cancer [https://clinicaltrials.gov/study/NCT00553332]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/17237274/]"]}}
{"disease": "liver cancer", "drug": "Altretamine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Apitolisib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Atorvastatin", "Q1": {"selection": "No", "clinicaltrial_references": ["Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment [https://clinicaltrials.gov/study/NCT03024684]", "The Combination Effect of Statin Plus Metformin on Relapse-free [https://clinicaltrials.gov/study/NCT02819869]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin. [https://pubmed.ncbi.nlm.nih.gov/40499501/]", "A Novel Ferroptosis-Related Gene Prognosis Signature and Identifying Atorvastatin as a Potential Therapeutic Agent for Hepatocellular Carcinoma. [https://pubmed.ncbi.nlm.nih.gov/40136455/]"]}}
{"disease": "liver cancer", "drug": "Axitinib", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT01273662]"]}}
{"disease": "liver cancer", "drug": "Azacitidine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Belotecan", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Bevacizumab", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma [https://clinicaltrials.gov/study/NCT03937830]", "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) [https://clinicaltrials.gov/study/NCT04524871]", "Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant [https://clinicaltrials.gov/study/NCT07059494]"]}}
{"disease": "liver cancer", "drug": "Buparlisib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Buparlisib and ponatinib inhibit aggressiveness of cholangiocarcinoma cells via suppression of IRS1-related pathway by targeting oxidative stress resistance. [https://pubmed.ncbi.nlm.nih.gov/39418964/]"]}}
{"disease": "liver cancer", "drug": "CH5126766", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Cabozantinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) [https://clinicaltrials.gov/study/NCT03963206]", "Cabozantinib to Treat Recurrent Liver Cancer Post Transplant [https://clinicaltrials.gov/study/NCT04204850]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Silmitasertib in Combination With Cabozantinib Impairs Liver Cancer Cell Cycle Progression, Induces Apoptosis, and Delays Tumor Growth in a Preclinical Model. [https://pubmed.ncbi.nlm.nih.gov/39377735/]", "SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model. [https://pubmed.ncbi.nlm.nih.gov/36017825/]"]}}
{"disease": "liver cancer", "drug": "Carboplatin", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Patients with Advanced Cholangiocarcinoma and Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT04175912]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer. [https://pubmed.ncbi.nlm.nih.gov/19391033/]", "Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. [https://pubmed.ncbi.nlm.nih.gov/16371540/]", "Intratumoral injection of boiling carboplatin (BCBP) solution for treatment of liver cancer in the animal model. [https://pubmed.ncbi.nlm.nih.gov/11677956/]"]}}
{"disease": "liver cancer", "drug": "Cenegermin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Cisplatin", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["AHEP0731, Treatment of Children With All Stages of Hepatoblastoma [https://clinicaltrials.gov/study/NCT00980460]"]}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Time of Day-Dependent Responses to Cisplatin Treatment in a Male Mouse Model of Hepatoma. [https://pubmed.ncbi.nlm.nih.gov/40703065/]", "Enhancing cisplatin efficacy in hepatocellular carcinoma with selenocystine: The suppression of DNA repair and inhibition of proliferation in hepatoma cells. [https://pubmed.ncbi.nlm.nih.gov/39461470/]"]}}
{"disease": "liver cancer", "drug": "Copanlisib", "Q1": {"selection": "No", "clinicaltrial_references": ["NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas [https://clinicaltrials.gov/study/NCT02465060]", "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT03735628]", "Study of Copanlisib in Hepatic or Renal Impairment [https://clinicaltrials.gov/study/NCT03172884]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/36158676/]"]}}
{"disease": "liver cancer", "drug": "Curcumin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms. [https://pubmed.ncbi.nlm.nih.gov/40685356/]", "Co-embedding of curcumin and gold nanoparticles with ZIF-8 nanoparticles for the treatment of liver cancer and its impact on metabolomics. [https://pubmed.ncbi.nlm.nih.gov/40484145/]", "Preparation and Evaluation of Hepatoma-Targeting Glycyrrhetinic Acid Composite Micelles Loaded with Curcumin. [https://pubmed.ncbi.nlm.nih.gov/40283886/]", "Formulation and optimization of glycyrrhetinic acid-modified pH-sensitive curcumin liposomes for anti-hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/39935270/]", "Preparation of oat galactolipid and anti-liver cancer effects of oat galactolipid-modified curcumin-loaded liver targeting vesicle. [https://pubmed.ncbi.nlm.nih.gov/39845799/]", "The bioconjugates of curcumin, zingerone and [6]-shogaol with low molecular weight chitosan: Synthesis, characterization and in vitro anticancer activity in HepG2 cells. [https://pubmed.ncbi.nlm.nih.gov/39805449/]", "Low-Intensity Continuous Ultrasound Enhances the Therapeutic Efficacy of Curcumin-Encapsulated Exosomes Derived from Hypoxic Liver Cancer Cells via Homotropic Drug Delivery Systems. [https://pubmed.ncbi.nlm.nih.gov/39768002/]", "The Combination of Sorafenib and PGV-1 Inhibits the Proliferation of Hepatocellular Carcinoma Through c-Myc Suppression in an Additive Manner: In Vitro Studies. [https://pubmed.ncbi.nlm.nih.gov/39628938/]", "Investigation of Folate-Functionalized Magnetic-Gold Nanoparticles Based Targeted Drug Delivery for Liver: In Vitro, In Vivo and Docking Studies. [https://pubmed.ncbi.nlm.nih.gov/39221994/]", "Role of Culinary Indian Spices in the Regulation of TGF-β Signaling Pathway in Inflammation-Induced Liver Cancer. [https://pubmed.ncbi.nlm.nih.gov/38766929/]", "Curcumin Encapsulation in Geranium Oil Microemulsion Elevates Its Antibacterial, Antioxidant, Anti-Inflammatory, and Anticancer Activities. [https://pubmed.ncbi.nlm.nih.gov/38343911/]", "Curcumin-loaded pH-sensitive carboxymethyl chitosan nanoparticles for the treatment of liver cancer. [https://pubmed.ncbi.nlm.nih.gov/38284334/]", "Discovery of Novel Mono-Carbonyl Curcumin Derivatives as Potential Anti-Hepatoma Agents. [https://pubmed.ncbi.nlm.nih.gov/37836639/]", "Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/37802456/]", "Anti-cancer effect of nano-encapsulated boswellic acids, curcumin and naringenin against HepG-2 cell line. [https://pubmed.ncbi.nlm.nih.gov/37516826/]", "k-Carrageenan based magnetic@polyelectrolyte complex composite hydrogel for pH and temperature-responsive curcumin delivery. [https://pubmed.ncbi.nlm.nih.gov/37336380/]", "Redox-Responsive Lipidic Prodrug Nano-Delivery System Improves Antitumor Effect of Curcumin Derivative C210. [https://pubmed.ncbi.nlm.nih.gov/37242789/]", "Curcumin and its Derivatives Targeting Multiple Signaling Pathways to Elicit Anticancer Activity: A Comprehensive Perspective. [https://pubmed.ncbi.nlm.nih.gov/37221681/]"]}}
{"disease": "liver cancer", "drug": "Cyclophosphamide", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["The protective effect and antitumor activity of Aconiti Lateralis Radix Praeparata (Fuzi) polysaccharide on cyclophosphamide-induced immunosuppression in H22 tumor-bearing mice. [https://pubmed.ncbi.nlm.nih.gov/37033618/]", "Grain-Sized Moxibustion Heightens the AntiTumor Effect of Cyclophosphamide in Hepa1-6 Bearing Mice. [https://pubmed.ncbi.nlm.nih.gov/35978996/]", "[Therapeutic effect of Panax notoginseng saponins combined with cyclophosphamide in mice bearing hepatocellular carcinoma H(22) cell xenograft]. [https://pubmed.ncbi.nlm.nih.gov/35527489/]", "Neutral polysaccharide from Panax notoginseng enhanced cyclophosphamide antitumor efficacy in hepatoma H22-bearing mice. [https://pubmed.ncbi.nlm.nih.gov/33413214/]", "Antitumor Effects of Ethanol Extracts from Hyptis Rhomboidea in H(22) Tumor-bearing Mice. [https://pubmed.ncbi.nlm.nih.gov/29200715/]"]}}
{"disease": "liver cancer", "drug": "Dactolisib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway. [https://pubmed.ncbi.nlm.nih.gov/32219609/]"]}}
{"disease": "liver cancer", "drug": "Docetaxel", "Q1": {"selection": "No", "clinicaltrial_references": ["QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors [https://clinicaltrials.gov/study/NCT03228667]", "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer [https://clinicaltrials.gov/study/NCT05249426]", "Docetaxel in Treating Patients With Recurrent or Refractory Solid Tumors [https://clinicaltrials.gov/study/NCT00002901]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Preparation of docetaxel-loaded, glycyrrhetinic acid-modified nanoparticles and their liver-targeting and antitumor activity. [https://pubmed.ncbi.nlm.nih.gov/34471430/]", "Docetaxel-decorated anticancer drug and gold nanoparticles encapsulated apatite carrier for the treatment of liver cancer. [https://pubmed.ncbi.nlm.nih.gov/29870961/]", "Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer. [https://pubmed.ncbi.nlm.nih.gov/29513882/]", "Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl(4)-induced hepatic fibrosis in mice. [https://pubmed.ncbi.nlm.nih.gov/29251522/]", "Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB(0,+)-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy. [https://pubmed.ncbi.nlm.nih.gov/27810556/]", "Novel fluorinated docetaxel analog for anti-hepatoma: Molecular docking and biological evaluation. [https://pubmed.ncbi.nlm.nih.gov/27058438/]", "Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer. [https://pubmed.ncbi.nlm.nih.gov/26602819/]", "Synthesis of cholic acid-core poly(ε-caprolactone-ran-lactide)-b-poly(ethylene glycol) 1000 random copolymer as a chemotherapeutic nanocarrier for liver cancer treatment. [https://pubmed.ncbi.nlm.nih.gov/32481897/]", "In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. [https://pubmed.ncbi.nlm.nih.gov/20973487/]"]}}
{"disease": "liver cancer", "drug": "Doxorubicin", "Q1": {"selection": "In phase III", "clinicaltrial_references": ["Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant [https://clinicaltrials.gov/study/NCT03960008]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["A novel self-assembled galactose/polysuccinimide-coated hydroxyapatite nanocarriers for targeted hepatic doxorubicin delivery. [https://pubmed.ncbi.nlm.nih.gov/41256913/]", "CD44 and mitochondria dual-targeted polydopamine nanoplatform for combined chemotherapy, photothermal ablation, and immunogenic cell death induction in liver cancer. [https://pubmed.ncbi.nlm.nih.gov/41218135/]", "Design, Synthesis, Cytotoxicity Assessment, and Molecular Docking of Novel Triazolopyrimidines as Potent Cyclin-Dependent Kinase 4 Inhibitors. [https://pubmed.ncbi.nlm.nih.gov/41176773/]", "pH-Responsive Modified Dextran Nanogel for Liver Targeted Doxorubicin Delivery. [https://pubmed.ncbi.nlm.nih.gov/41149389/]", "Self-Adjuvanting Gel for Hierarchical Delivery to Tumors and Lymph Nodes in Liver and Colon Tumor Immunotherapy. [https://pubmed.ncbi.nlm.nih.gov/41026501/]", "CAPG Regulates Doxorubicin Resistance in Hepatocellular Carcinoma Cells via TGFB1/Smad/Nrf2 Signalling Pathway. [https://pubmed.ncbi.nlm.nih.gov/40982354/]", "Asialoglycoprotein receptor-1 mediated targeted drug delivery to liver cancer cells using stimuli responsive galactosylated electrospun nanofibers. [https://pubmed.ncbi.nlm.nih.gov/40975359/]", "Combined nanodiamond-mediated drug delivery and upconversion phototherapy for enhanced liver cancer treatment. [https://pubmed.ncbi.nlm.nih.gov/40945052/]", "Natural Phytochemicals from Macaranga conglomerata Brenan: A Cytotoxic and Computational Analysis against Cancer Targets. [https://pubmed.ncbi.nlm.nih.gov/40757329/]", "[Glycyrrhetinic acid combined with doxorubicin induces apoptosis of human hepatocellular carcinoma HepG2 cells by regulating ERMMDs]. [https://pubmed.ncbi.nlm.nih.gov/40686177/]", "Melanin Nanoparticle-Enabled Local Drug Delivery Platform for Preventing Postoperative Recurrence of Liver Cancer. [https://pubmed.ncbi.nlm.nih.gov/40611516/]", "Multi-Focused Acoustic Radiation Force Impulse Modulation of Murine Hepatic Xenografts Enhances Nanoscale DOX@Lip Delivery and Therapeutic Effect. [https://pubmed.ncbi.nlm.nih.gov/40529535/]", "A salophen-type macrocyclic Schiff base ligand and its metal complexes: exploring in vitro anticancer efficacy via in silico topoisomerase IIβ enzyme targeting. [https://pubmed.ncbi.nlm.nih.gov/40512013/]", "Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin. [https://pubmed.ncbi.nlm.nih.gov/40499501/]", "Glycyrrhetinic acid and RGD dual-targeted liposomes for combined chemotherapy and phototherapy in liver cancer. [https://pubmed.ncbi.nlm.nih.gov/40456423/]", "In Vitro Evaluation of the Dual Pharmacological Action of Vitamin D(3) as Cardio-protectant and Anti-cancer Agent. [https://pubmed.ncbi.nlm.nih.gov/40425342/]", "Feather keratin-tea polyphenol nanoparticles with pH and reduction dually responsive for tumor-targeting DOX transmit. [https://pubmed.ncbi.nlm.nih.gov/40414380/]", "Phytochemical Analysis and In Vivo Anticancer Effect of Becium grandiflorum: Isolation and Characterization of a Promising Cytotoxic Diterpene. [https://pubmed.ncbi.nlm.nih.gov/40218923/]", "Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX. [https://pubmed.ncbi.nlm.nih.gov/40165796/]", "Synthesis and Characterization of Zn(1-x-y)MnxCoyO NPs for Liver Cancer Treatment. [https://pubmed.ncbi.nlm.nih.gov/40103461/]"]}}
{"disease": "liver cancer", "drug": "Drostanolone propion", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Epigallocatechin gallate (EGCG)", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["EGCG for Hepatocellular Carcinoma Chemoprevention [https://clinicaltrials.gov/study/NCT06015022]", "A Phase II Study of Polyphenon E in Patients With Liver Fibrosis [https://clinicaltrials.gov/study/NCT03278925]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Unveiling the therapeutic potential of epigallocatechin gallate in liver cancer: insights from network pharmacology and in vitro assays. [https://pubmed.ncbi.nlm.nih.gov/39093995/]", "Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine‑induced liver cancer via inhibition of cell division cycle 25A. [https://pubmed.ncbi.nlm.nih.gov/33000276/]", "Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer. [https://pubmed.ncbi.nlm.nih.gov/29715531/]", "Improving the Anticancer Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs) via ROS-Dependent Apoptosis in SMMC-7721 Cells. [https://pubmed.ncbi.nlm.nih.gov/26018505/]", "Epigallocatechin-3-gallate inhibits hepatoblastoma growth by reactivating the Wnt inhibitor SFRP1. [https://pubmed.ncbi.nlm.nih.gov/24127655/]", "Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. [https://pubmed.ncbi.nlm.nih.gov/20514403/]"]}}
{"disease": "liver cancer", "drug": "Floxuridine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Gefitinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT04642547]", "Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT00282100]", "Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) [https://clinicaltrials.gov/study/NCT00071994]"]}}
{"disease": "liver cancer", "drug": "Gemcitabine", "response": [{"study_summary": {"title": "A Phase I/II Study of Durvalumab in Combination with Cisplatin and Gemcitabine in Patients with Advanced Solid Tumors", "NCTID": "NCT06050252", "drug_for_treatment": ["Durvalumab", "Cisplatin", "Gemcitabine"], "indication": "Advanced Solid Tumors", "result_summary_sentence": "The study is ongoing and has not yet posted results.", "phase": "Phase I/II", "risk_level": "High", "positive_or_negative": "", "population_summary": "Patients with advanced solid tumors", "has_results": false, "sample_size": 100, "start_year": 2023, "this_year-start_year": 0, "complete_year": null}, "scoring": {"mechanism": {"score": 85, "explanation": "Durvalumab is a PD-L1 inhibitor, which is a well-validated target in oncology. Cisplatin and Gemcitabine are established chemotherapeutic agents. The combination of immunotherapy with chemotherapy has shown promise in various cancers."}, "clinical_evidence": {"score": 50, "explanation": "The study is in early phases (I/II) and has not yet posted results. However, the combination of these drugs has shown potential in preclinical models and other clinical settings."}, "safety_predictability": {"score": 60, "explanation": "The safety profiles of Durvalumab, Cisplatin, and Gemcitabine are well-documented. However, the combination may present unique toxicities that need to be closely monitored."}, "trial_quality": {"score": 70, "explanation": "The trial design appears robust with a clear focus on advanced solid tumors. The endpoints and inclusion criteria are appropriate for detecting meaningful clinical signals."}, "result_status": {"score": 75, "category": "ongoing_in_reasonable_term", "explanation": "The study started in 2023 and is still ongoing, which is within a reasonable timeframe for a Phase I/II trial."}, "target_drug_importance": {"score": 90, "role": "major", "explanation": "Durvalumab is the primary experimental agent in this study, making its individual contribution critical to the study's outcome."}, "overall_confidence": {"score": 70, "explanation": "The investigational drug combination has a strong mechanistic rationale and is supported by preclinical evidence. The trial is well-designed, but the lack of clinical results limits the confidence level to high rather than very high."}}, "nct_id": "NCT06050252"}, {"study_summary": {"title": "PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma", "NCTID": "NCT05286814", "drug_for_treatment": ["PDS01ADC"], "indication": "Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Metastatic Adrenocortical Carcinoma", "result_summary_sentence": "The study is currently recruiting and has not yet posted results.", "phase": "Phase II", "risk_level": "High", "positive_or_negative": "", "population_summary": "Adults with metastatic colorectal cancer, intrahepatic cholangiocarcinoma, or metastatic adrenocortical carcinoma who have progressed by RECIST criteria in the preceding 3 months prior to study enrollment.", "has_results": false, "sample_size": 60, "start_year": 2022, "this_year-start_year": 1, "complete_year": null}, "scoring": {"mechanism": {"score": 75, "explanation": "PDS01ADC is an antibody-drug conjugate targeting a relevant pathway in metastatic colorectal cancer and intrahepatic cholangiocarcinoma. Similar mechanisms have shown promise in preclinical models and early clinical trials."}, "clinical_evidence": {"score": 50, "explanation": "The study is in Phase II and currently recruiting, with no posted results yet. Early clinical signals are not available, making the evidence moderate."}, "safety_predictability": {"score": 60, "explanation": "Expected toxicities based on the mechanism are manageable, and the combination with HAIP and systemic therapy is anticipated to be tolerable."}, "trial_quality": {"score": 65, "explanation": "The trial design is robust with a clear focus on advanced solid tumors. The endpoints and inclusion criteria are appropriate for detecting meaningful clinical signals."}, "result_status": {"score": 60, "category": "ongoing_in_reasonable_term", "explanation": "The study started in 2022 and is still ongoing, which is within a reasonable timeframe for a Phase II trial."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "PDS01ADC is the primary experimental agent in this study, making its individual contribution critical to the study's outcome."}, "overall_confidence": {"score": 65, "explanation": "The investigational drug combination has a strong mechanistic rationale and is supported by preclinical evidence. The trial is well-designed, but the lack of clinical results limits the confidence level to moderate rather than high."}}, "nct_id": "NCT05286814"}, {"study_summary": {"title": "A Phase II Study of Cisplatin, Doxorubicin, Carboplatin, Fluorouracil, Vincristine, Etoposide, Irinotecan, Gemcitabine, Oxaliplatin, and Sorafenib in Pediatric Patients with Hepatic Tumors", "NCTID": "NCT03017326", "drug_for_treatment": ["Cisplatin", "Doxorubicin", "Carboplatin", "Fluorouracil", "Vincristine", "Etoposide", "Irinotecan", "Gemcitabine", "Oxaliplatin", "Sorafenib"], "indication": "Hepatoblastoma, Carcinoma, Hepatocellular", "result_summary_sentence": "No results posted yet.", "phase": "Phase II", "risk_level": "Moderate", "positive_or_negative": "N/A", "population_summary": "Paediatric patients with hepatic tumors", "has_results": false, "sample_size": 200, "start_year": 2017, "this_year-start_year": 6, "complete_year": null}, "scoring": {"mechanism": {"score": 75, "explanation": "The drugs used in this trial target various mechanisms relevant to hepatic tumors, including DNA damage, inhibition of topoisomerase, and kinase inhibition. These mechanisms are well-established in oncology and have shown efficacy in similar indications."}, "clinical_evidence": {"score": 40, "explanation": "The trial is ongoing and has not posted results yet. While the drugs involved have shown efficacy in other settings, the lack of specific clinical data from this trial limits confidence."}, "safety_predictability": {"score": 60, "explanation": "The safety profiles of the drugs used are well-documented, with known toxicities. However, the combination of multiple agents may present unpredictable safety concerns."}, "trial_quality": {"score": 55, "explanation": "The trial design appears robust with a reasonable sample size and clear endpoints. However, the lack of posted results and the extended timeline without completion data reduce confidence."}, "result_status": {"score": 45, "category": "ongoing_long_term_incomplete", "explanation": "The study has been ongoing for over 6 years without posted results, which is beyond the typical timeline for Phase II trials, indicating potential issues with data collection or analysis."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "The investigational drugs are central to the study's treatment regimen, making their individual contributions directly informative for evaluating the trial's outcomes."}, "overall_confidence": {"score": 55, "explanation": "Moderate confidence due to the strong mechanistic rationale and known safety profiles of the drugs, but limited by the lack of clinical evidence and extended trial duration without results."}}, "nct_id": "NCT03017326"}]}
{"disease": "liver cancer", "drug": "Gilteritinib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Lenvatinib", "Q1": {"selection": "FDA-Approved to liver cancer", "clinicaltrial_references": ["A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread [https://clinicaltrials.gov/study/NCT07256223]", "ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC [https://clinicaltrials.gov/study/NCT07157969]", "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) [https://clinicaltrials.gov/study/NCT05822752]"]}}
{"disease": "liver cancer", "drug": "Liraglutide", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps. [https://pubmed.ncbi.nlm.nih.gov/36271684/]", "Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. [https://pubmed.ncbi.nlm.nih.gov/32785012/]"]}}
{"disease": "liver cancer", "drug": "MK-2206", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["A Phase I Study of Akt Inhibitor MK2206 in Patients With Advanced Hepatocellular Carcinoma or Biliary Cancer [https://clinicaltrials.gov/study/NCT01425879]", "A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT01239355]", "Phase I/II Study of MK-2206 and AZD6244 Hydrogen Sulfate in Patients With Biliary Cancer [https://clinicaltrials.gov/study/NCT01859182]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Polyphenolic Proanthocyanidin-B2 suppresses proliferation of liver cancer cells and hepatocellular carcinogenesis through directly binding and inhibiting AKT activity. [https://pubmed.ncbi.nlm.nih.gov/32863234/]"]}}
{"disease": "liver cancer", "drug": "Melphalan", "Q1": {"selection": "No", "clinicaltrial_references": ["Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease [https://clinicaltrials.gov/study/NCT06607458]", "Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases [https://clinicaltrials.gov/study/NCT04812470]", "Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases [https://clinicaltrials.gov/study/NCT00019786]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. [https://pubmed.ncbi.nlm.nih.gov/16148157/]"]}}
{"disease": "liver cancer", "drug": "Nifurtimox", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Olaparib", "Q1": {"selection": "Completed phase I with positive result (or FDA-Approved for other diseases)", "clinicaltrial_references": ["Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment [https://clinicaltrials.gov/study/NCT01894243]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model. [https://pubmed.ncbi.nlm.nih.gov/39859548/]", "Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors. [https://pubmed.ncbi.nlm.nih.gov/37556368/]", "Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR/PARP-1 Targeting Breast and Liver Cancer Cells. [https://pubmed.ncbi.nlm.nih.gov/36530255/]", "Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. [https://pubmed.ncbi.nlm.nih.gov/34037269/]", "BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. [https://pubmed.ncbi.nlm.nih.gov/32642299/]"]}}
{"disease": "liver cancer", "drug": "PD0325901", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Paclitaxel", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT04175912]", "A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor [https://clinicaltrials.gov/study/NCT04008797]"]}}
{"disease": "liver cancer", "drug": "Perifosine", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers [https://clinicaltrials.gov/study/NCT00398814]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Hiwi overexpression does not affect proliferation, migration or apoptosis of liver cancer cells in vitro or in vivo. [https://pubmed.ncbi.nlm.nih.gov/29928347/]"]}}
{"disease": "liver cancer", "drug": "Quercetin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Quercetin regulates sensitivity to X-ray radiation of hepatocellular carcinoma through miR-216a-3p. [https://pubmed.ncbi.nlm.nih.gov/39508798/]", "Quercetin-primed BMSC-derived extracellular vesicles ameliorate chronic liver damage through miR-136-5p and GNAS/STAT3 signaling pathways. [https://pubmed.ncbi.nlm.nih.gov/39340996/]", "Study on the mechanism of quercetin in Sini Decoction Plus Ginseng Soup to inhibit liver cancer and HBV virus replication through CDK1. [https://pubmed.ncbi.nlm.nih.gov/38858165/]", "Fabrication and in vitro/vivo evaluation of quercetin nanocrystals stabilized by glycyrrhizic acid for liver targeted drug delivery. [https://pubmed.ncbi.nlm.nih.gov/38628619/]"]}}
{"disease": "liver cancer", "drug": "Radium Ra 223 dichlo", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Ramucirumab", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT01140347]", "Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy [https://clinicaltrials.gov/study/NCT00627042]"]}, "Q2": {"selection": "", "literature_references": []}}
{"disease": "liver cancer", "drug": "Refametinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) [https://clinicaltrials.gov/study/NCT01915602]", "Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) [https://clinicaltrials.gov/study/NCT01915589]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Regorafenib", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["Regorafenib and Durvalumab for Advanced Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT05194293]", "Regorafenib and Nivolumab for Advanced Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT04170556]"]}}
{"disease": "liver cancer", "drug": "Resveratrol", "Q1": {"selection": "No", "clinicaltrial_references": ["Resveratrol and Human Hepatocyte Function in Cancer [https://clinicaltrials.gov/study/NCT02261844]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Resveratrol Derivatives with a Urea Backbone Exert Anticancer Effects against Liver Cancer via Apoptosis Induction and Metastasis Inhibition. [https://pubmed.ncbi.nlm.nih.gov/41324234/]", "Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacy. [https://pubmed.ncbi.nlm.nih.gov/39023830/]", "Resveratrol inhibits the migration, invasion and epithelial-mesenchymal transition in liver cancer cells through up- miR-186-5p expression. [https://pubmed.ncbi.nlm.nih.gov/34986537/]", "Nano-Gold Loaded with Resveratrol Enhance the Anti-Hepatoma Effect of Resveratrol In Vitro and In Vivo. [https://pubmed.ncbi.nlm.nih.gov/30596551/]"]}}
{"disease": "liver cancer", "drug": "Rucaparib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Selumetinib", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["Selumetinib in Treating Patients With Liver Cancer [https://clinicaltrials.gov/study/NCT00553332]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. [https://pubmed.ncbi.nlm.nih.gov/30030148/]"]}}
{"disease": "liver cancer", "drug": "Sorafenib", "Q1": {"selection": "FDA-Approved to liver cancer", "clinicaltrial_references": ["QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy [https://clinicaltrials.gov/study/NCT03167177]", "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT03298451]", "Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT05713994]"]}}
{"disease": "liver cancer", "drug": "TAK-733", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Talaporfin", "Q1": {"selection": "In phase III", "clinicaltrial_references": ["A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) [https://clinicaltrials.gov/study/NCT00355355]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Temsirolimus", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis [https://clinicaltrials.gov/study/NCT01079767]"]}, "Q2": {"selection": "", "literature_references": []}}
{"disease": "liver cancer", "drug": "Thiotepa", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "MT2004-30: Tomotherapy for Solid Tumors", "NCTID": "NCT00623077", "drug_for_treatment": ["Busulfan", "Etoposide", "Ifosfamide", "Melphalan", "Thiotepa", "Mesna"], "indication": "Solid Tumors", "result_summary_sentence": "The study is focused on dose escalation of total marrow irradiation added to an alkylator-intensive conditioning regimen for patients with advanced solid tumors.", "phase": "Phase I", "risk_level": "High", "positive_or_negative": "Neutral", "population_summary": "Patients with advanced solid tumors including carcinoma, renal cell, astrocytoma, familial ependymoma, medulloblastoma, optic nerve glioma, rhabdoid tumor.", "has_results": false, "sample_size": 50, "start_year": 2005, "this_year-start_year": 18, "complete_year": null}, "scoring": {"mechanism": {"score": 70, "explanation": "The mechanistic rationale is moderately strong as total marrow irradiation combined with alkylating agents is a known approach to target solid tumors. However, the specific combination and its efficacy in this context are not fully established."}, "clinical_evidence": {"score": 35, "explanation": "The study has been ongoing for a significant period (18 years) without posted results, which suggests weak clinical evidence. The lack of published data or results diminishes confidence in the investigational drug's efficacy."}, "safety_predictability": {"score": 50, "explanation": "Expected toxicities based on the mechanism include marrow suppression and other alkylator-related toxicities. The safety profile is predictable but requires careful monitoring."}, "trial_quality": {"score": 60, "explanation": "The trial design includes dose escalation and a combination regimen, which are appropriate for Phase I studies. However, the long duration without results impacts the perceived quality."}, "result_status": {"score": 35, "category": "ongoing_long_term_incomplete", "explanation": "The study has been ongoing for 18 years without posted results, which exceeds normal development timelines for Phase I trials, indicating long-term incomplete status."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "The investigational drugs are central to the study outcome as they are part of the conditioning regimen combined with total marrow irradiation."}, "overall_confidence": {"score": 45, "explanation": "Overall confidence is moderate due to the strong mechanistic rationale and trial design quality, but significantly impacted by the lack of clinical evidence and long-term incomplete status."}}, "nct_id": "NCT00623077"}, {"study_summary": {"title": "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer", "NCTID": "NCT00002515", "drug_for_treatment": ["Filgrastim", "Carboplatin", "Thiotepa", "Topotecan"], "indication": "Rare Poor-Prognosis Cancers", "result_summary_sentence": "The study aims to evaluate the efficacy of combination chemotherapy followed by bone marrow transplantation in patients with rare poor-prognosis cancers.", "phase": "Phase I/II", "risk_level": "High", "positive_or_negative": "Unknown", "population_summary": "Patients with rare poor-prognosis cancers including head and neck neoplasms, kidney neoplasms, liver neoplasms, lymphoma, neuroblastoma, ovarian neoplasms, retinoblastoma, sarcoma, testicular germ cell tumor, chondrosarcoma, Wilms tumor, osteosarcoma, testicular neoplasms, fibrosarcoma, desmoplastic small round cell tumor, Burkitt lymphoma, dendritic cell sarcoma, interdigitating, neuroectodermal tumors, primitive, peripheral.", "has_results": false, "sample_size": 0, "start_year": 1992, "this_year-start_year": 31, "complete_year": null}, "scoring": {"mechanism": {"score": 70, "explanation": "The mechanistic rationale is moderately strong as the combination chemotherapy targets multiple pathways relevant to cancer biology. Filgrastim is a granulocyte colony-stimulating factor, carboplatin is a platinum-based chemotherapy, thiotepa is an alkylating agent, and topotecan is a topoisomerase inhibitor. These mechanisms are known to be effective in various cancers, but the specific combination's efficacy in rare cancers is less established."}, "clinical_evidence": {"score": 30, "explanation": "There is limited clinical evidence available from this study as it has not posted results despite being initiated in 1992. The lack of published data or results weakens the confidence in clinical efficacy."}, "safety_predictability": {"score": 50, "explanation": "The safety profile of the drugs involved is relatively well-known, with expected toxicities such as myelosuppression, nephrotoxicity, and gastrointestinal side effects. However, the combination therapy's safety in the context of bone marrow transplantation for rare cancers is less predictable."}, "trial_quality": {"score": 40, "explanation": "The trial design includes combination chemotherapy followed by bone marrow transplantation, which is a complex and high-risk approach. The endpoints and inclusion criteria are not detailed, making it difficult to assess the quality of signal detection."}, "result_status": {"score": 35, "category": "ongoing_long_term_incomplete", "explanation": "The study has been ongoing for over 31 years without posted results, indicating long-term incompleteness and weak clinical evidence."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "The investigational drugs are central to the study's outcome as they are the primary experimental agents being evaluated for efficacy in combination chemotherapy followed by bone marrow transplantation."}, "overall_confidence": {"score": 45, "explanation": "Overall confidence is moderate due to the strong mechanistic rationale and known safety profiles of the drugs, but significantly weakened by the lack of clinical evidence and long-term incompleteness of the study."}}, "nct_id": "NCT00002515"}]}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Establishment and experimental study of a transplantable hepatocellular carcinoma model in 615-strain mice (H 615). [https://pubmed.ncbi.nlm.nih.gov/3447859/]"]}}
{"disease": "liver cancer", "drug": "Topotecan", "Q1": {"selection": "No", "clinicaltrial_references": ["Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer [https://clinicaltrials.gov/study/NCT00002515]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma. [https://pubmed.ncbi.nlm.nih.gov/41237570/]", "Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I. [https://pubmed.ncbi.nlm.nih.gov/37390632/]", "Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action. [https://pubmed.ncbi.nlm.nih.gov/25309924/]"]}}
{"disease": "liver cancer", "drug": "Trabectedin", "Q1": {"selection": "No", "clinicaltrial_references": ["Tabectedin to Treat Children and Adolescents With Cancer [https://clinicaltrials.gov/study/NCT01453283]", "A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction [https://clinicaltrials.gov/study/NCT01273493]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Trametinib", "Q1": {"selection": "No", "clinicaltrial_references": ["NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas [https://clinicaltrials.gov/study/NCT02465060]", "Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction [https://clinicaltrials.gov/study/NCT02070549]", "Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer [https://clinicaltrials.gov/study/NCT02292173]", "A Randomized Phase II Study of Single Agent MEK Inhibitor Trametinib vs. 5-Fluorouracil or Capecitabine in Patients with Advanced Refractory Biliary Cancer [https://clinicaltrials.gov/study/NCT02042443]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. [https://pubmed.ncbi.nlm.nih.gov/27956228/]", "Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. [https://pubmed.ncbi.nlm.nih.gov/27117591/]"]}}
{"disease": "liver cancer", "drug": "Tretamine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "Trifarotene", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "liver cancer", "drug": "U0126", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. [https://pubmed.ncbi.nlm.nih.gov/17088989/]"]}}
{"disease": "liver cancer", "drug": "Vitamin D", "Q1": {"selection": "No", "clinicaltrial_references": ["The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes [https://clinicaltrials.gov/study/NCT01047735]", "Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases [https://clinicaltrials.gov/study/NCT02172651]", "The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List [https://clinicaltrials.gov/study/NCT01575717]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["In Vitro Evaluation of the Dual Pharmacological Action of Vitamin D(3) as Cardio-protectant and Anti-cancer Agent. [https://pubmed.ncbi.nlm.nih.gov/40425342/]", "Vitamin D receptor attenuates carbon tetrachloride-induced liver fibrosis via downregulation of YAP. [https://pubmed.ncbi.nlm.nih.gov/39146589/]", "Vitamin D ameliorates diethylnitrosamine-induced liver preneoplasia: A pivotal role of CYP3A4/CYP2E1 via DPP-4 enzyme inhibition. [https://pubmed.ncbi.nlm.nih.gov/36442531/]", "Vitamin D: Possible Therapeutic Roles in Hepatocellular Carcinoma. [https://pubmed.ncbi.nlm.nih.gov/34113565/]", "Hypoxia as a modulator of cytochromes P450: Overexpression of the cytochromes CYP2S1 and CYP24A1 in human liver cancer cells in hypoxia. [https://pubmed.ncbi.nlm.nih.gov/33377261/]", "Inhibition of vitamin D analog eldecalcitol on hepatoma in vitro and in vivo. [https://pubmed.ncbi.nlm.nih.gov/33336024/]", "p62 functions as an oncogene in colorectal cancer through inhibiting apoptosis and promoting cell proliferation by interacting with the vitamin D receptor. [https://pubmed.ncbi.nlm.nih.gov/30793399/]", "Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor-β/Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation. [https://pubmed.ncbi.nlm.nih.gov/27456065/]", "Hepatocellular carcinoma cells express 25(OH)D-1α-hydroxylase and are able to convert 25(OH)D to 1α,25(OH)₂D, leading to the 25(OH)D-induced growth inhibition. [https://pubmed.ncbi.nlm.nih.gov/26170242/]", "Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/24451003/]", "Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/22677193/]", "Vitamin D and the vitamin D receptor in liver pathophysiology. [https://pubmed.ncbi.nlm.nih.gov/21440524/]"]}}
{"disease": "liver cancer", "drug": "lvosidenib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
